BC Innovations | Dec 13, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest FASL inhibitors could help treat immunotherapy-resistant melanoma. In a mouse model of immunotherapy-resistant melanoma, a fusion protein consisting of Fas receptor and the Fc region of murine IgG2A (Fas-Fc) that...
BC Innovations | May 8, 2017
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; sarcoma Patient sample and mouse studies suggest an antibody-dependent cellular cytotoxicity (ADCC)-optimized chimeric mab against CD25 could help treat colorectal cancer and sarcoma. The antibody consisted of the antigen-binding domain of a...
BC Innovations | Jul 28, 2016
Targets & Mechanisms

Effectorless efficacy

In a finding that might solve the problem of dose-limiting side effects for using antibodies in CNS disorders, a Genentech-led team has engineered an anti-tau antibody for Alzheimer's disease that binds its target in the...
BC Innovations | May 7, 2015
Distillery Therapeutics

Therapeutics: Interleukin-2 (IL-2)

Cancer INDICATION: Cancer Mouse studies suggest an IL-2 fusion protein could help treat cancer by boosting the efficacy of tumor-targeting mAbs. Mouse IL-2 was fused to the Fc domain of mouse immunoglobulin G2a (IgG2a) to...
BC Innovations | May 9, 2013
Targets & Mechanisms

AD vaccine redux

Researchers at Harvard Medical School have teamed up with vaccine maker Mercia Pharma Inc. to design a next-generation Alzheimer's disease vaccine with an adjuvant that promotes a beneficial anti-inflammatory response that the team hopes will...
BC Week In Review | May 21, 2012
Clinical News

Peregrine preclinical data

In a mouse model of AMD, intravitreal PGN632 significantly reduced the size of laser-induced choroidal neovascularization (CNV) in the retina by 52% vs. mouse immunoglobulin G2a (IgG2a) negative control (p=0.02). Data were presented at the...
BC Innovations | Mar 1, 2012
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of Epstein-Barr virus (EBV)-driven B cell lymphoma Mice that express EBV latent membrane protein 1 (Lmp-1) in B cells could aid the development...
BC Week In Review | Sep 5, 2011
Clinical News

NanoBio preclinical data

In mice, vaccination with NanoBio's intranasal nanoemulsion-adjuvanted inactivated respiratory syncytial virus (RSV) vaccine significantly increased levels of RSV-specific immunoglobulin A (IgA) , IgG2a and IgG1 antibodies at week 8 vs. unvaccinated mice (p<0.01 for all), but...
BC Innovations | Sep 1, 2011
Targets & Mechanisms

Notch one for activating NOTCH

Multiple studies in recent years have called into question the use of NOTCH inhibitors to treat cancer because of an increased risk of endothelial cell tumors seen in animal models. 1 Now, researchers at Vanderbilt...
BC Innovations | Jan 14, 2010
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Self-assembling peptides for immunotherapy In vitro and mouse studies suggest that self-assembling peptide epitopes could help increase vaccine immunogenicity. The self-assembling peptide Q11 was conjugated...
Items per page:
1 - 10 of 19